The table below shows Bristol-Myers Squibb Company's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q3 2022
Q1 2022
Operating cash flow
$1.10B
$1.95B
$2.83B
$2.97B
-
$3.81B
Capital expenditure
$347.00M
$260.00M
$284.00M
$278.00M
-
$253.00M
Investing cash flow
-$131.00M
-$499.00M
-$19.62B
-$210.00M
-
$95.00M
Dividends paid
$1.28B
$1.26B
$1.21B
$1.20B
-
BMY operating cash flow (10-K history)
Bristol-Myers Squibb Company reported operating cash flow of $14.16B for fiscal year 2025. That is down 6.8% from $15.19B in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $3.06B (FY 2016) to $14.16B. Figures come from the company's audited annual reports as filed with the SEC.
